Format

Send to

Choose Destination
Adv Chronic Kidney Dis. 2016 Mar;23(2):120-4. doi: 10.1053/j.ackd.2016.01.017.

Genomics in CKD: Is This the Path Forward?

Author information

1
Department of Medicine, Division of Nephrology, Icahn School of Medicine, New York, NY; Department of Population Health Science and Policy, Icahn School of Medicine, New York, NY; and Department of Medicine, Icahn School of Medicine, New York, NY.
2
Department of Medicine, Division of Nephrology, Icahn School of Medicine, New York, NY; Department of Population Health Science and Policy, Icahn School of Medicine, New York, NY; and Department of Medicine, Icahn School of Medicine, New York, NY. Electronic address: carol.horowitz@mountsinai.org.

Abstract

Recent advances in genomics and sequencing technology have led to a better understanding of genetic risk in CKD. Genetics could account in part for racial differences in treatment response for medications including antihypertensives and immunosuppressive medications due to its correlation with ancestry. However, there is still a substantial lag between generation of this knowledge and its adoption in routine clinical care. This review summarizes the recent advances in genomics and CKD, discusses potential reasons for its underutilization, and highlights potential avenues for application of genomic information to improve clinical care and outcomes in this particularly vulnerable population.

KEYWORDS:

CKD; Disparities; Genetics; Genomics; Pharmacogenomics

PMID:
26979150
PMCID:
PMC4795469
[Available on 2017-03-01]
DOI:
10.1053/j.ackd.2016.01.017
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center